AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY OF EPLONTERSEN
(ION-682884) IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY
(ATTR-CM)
- Registry ID
- ION-682884-CS12
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- IONIS PHARMACEUTICALS INC
- Start date
- 2024-05-01
- Last update
- 2023-06-22
Conditions
- TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Related clinical trials
- A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CONCOMITANT USE OF EPLONTERSEN AND ALXN2220 COMPARED WITH EPLONTERSEN AND PLACEBO IN ADULT PARTICIPANTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
- CLEOPATTRA: EFFECTS OF NNC6019-0001 VERSUS PLACEBO ON CARDIOVASCULAR
OUTCOMES IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRCM)
- A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF ACORAMIDIS IN PATIENTS
WITH NEWLY DIAGNOSED VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ACTEARLY OLE)
- MAGNITUDE: A PHASE 3, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR-CM)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF AMYLOID DEPLETER ALXN2220 IN ADULT
PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
- EFFICACY ANDD SAFETY OF NNC6019-0001 AT TWO DOSE LEVELS IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM)
View on source registry